Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
Abstract Background Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI). However, this has not been fully establi...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6452d84482df43b7a070b79879e835ef |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:6452d84482df43b7a070b79879e835ef |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:6452d84482df43b7a070b79879e835ef2021-11-21T12:30:40ZAssociation between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study10.1186/s12885-021-08983-21471-2407https://doaj.org/article/6452d84482df43b7a070b79879e835ef2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08983-2https://doaj.org/toc/1471-2407Abstract Background Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI). However, this has not been fully established. This study aimed to evaluate the predominant progressive disease (PD) pattern limited to residual sites of disease after treatment with EGFR-TKI. Methods Patients with advanced EGFR-mutated NSCLC treated with EGFR-TKIs as first-line therapy were retrospectively analysed during a 7-year period. Oligo-residual disease was defined as the presence of 1 – 4 lesions (including the primary site) at 3 months from the start of EGFR-TKI treatment. The predictive factors of PD patterns after EGFR-TKI treatment were evaluated. Results A total of 207 patients were included. Three months after the start of EGFR-TKI treatment, 66 patients (32%) had oligo-residual disease. A total of 191 patients had PD, 60 with oligo-residual disease and 131 with non-oligo-residual disease. Regarding the pattern, 44 patients (73%) with oligo-residual disease and 37 patients (28%) with non-oligo-residual disease had PD limited to the residual sites. Multivariate logistic regression analysis at 3 months from the start of EGFR-TKI treatment revealed that oligo-residual disease (P < 0.001), the lack of residual central nervous system metastases (P = 0.032), and initial treatment with osimertinib (P = 0.028) were independent predictors of PD limited to residual disease sites. Conclusions This study provided a rationale for LAT to all sites of residual disease in patients with oligo-residual disease during EGFR-TKI treatment.Taichi MiyawakiHirotsugu KenmotsuHiroaki KodamaNaoya NishiokaEriko MiyawakiNobuaki MamesayaHaruki KobayashiShota OmoriRyo KoKazushige WakudaAkira OnoTateaki NaitoHaruyasu MurakamiKeita MoriHideyuki HaradaMasahiro EndoKazuhisa TakahashiToshiaki TakahashiBMCarticleNon-small-cell lung cancerOligo-residual diseaseFailure patternEGFR-TKIOsimertinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Non-small-cell lung cancer Oligo-residual disease Failure pattern EGFR-TKI Osimertinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
spellingShingle |
Non-small-cell lung cancer Oligo-residual disease Failure pattern EGFR-TKI Osimertinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Taichi Miyawaki Hirotsugu Kenmotsu Hiroaki Kodama Naoya Nishioka Eriko Miyawaki Nobuaki Mamesaya Haruki Kobayashi Shota Omori Ryo Ko Kazushige Wakuda Akira Ono Tateaki Naito Haruyasu Murakami Keita Mori Hideyuki Harada Masahiro Endo Kazuhisa Takahashi Toshiaki Takahashi Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study |
description |
Abstract Background Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI). However, this has not been fully established. This study aimed to evaluate the predominant progressive disease (PD) pattern limited to residual sites of disease after treatment with EGFR-TKI. Methods Patients with advanced EGFR-mutated NSCLC treated with EGFR-TKIs as first-line therapy were retrospectively analysed during a 7-year period. Oligo-residual disease was defined as the presence of 1 – 4 lesions (including the primary site) at 3 months from the start of EGFR-TKI treatment. The predictive factors of PD patterns after EGFR-TKI treatment were evaluated. Results A total of 207 patients were included. Three months after the start of EGFR-TKI treatment, 66 patients (32%) had oligo-residual disease. A total of 191 patients had PD, 60 with oligo-residual disease and 131 with non-oligo-residual disease. Regarding the pattern, 44 patients (73%) with oligo-residual disease and 37 patients (28%) with non-oligo-residual disease had PD limited to the residual sites. Multivariate logistic regression analysis at 3 months from the start of EGFR-TKI treatment revealed that oligo-residual disease (P < 0.001), the lack of residual central nervous system metastases (P = 0.032), and initial treatment with osimertinib (P = 0.028) were independent predictors of PD limited to residual disease sites. Conclusions This study provided a rationale for LAT to all sites of residual disease in patients with oligo-residual disease during EGFR-TKI treatment. |
format |
article |
author |
Taichi Miyawaki Hirotsugu Kenmotsu Hiroaki Kodama Naoya Nishioka Eriko Miyawaki Nobuaki Mamesaya Haruki Kobayashi Shota Omori Ryo Ko Kazushige Wakuda Akira Ono Tateaki Naito Haruyasu Murakami Keita Mori Hideyuki Harada Masahiro Endo Kazuhisa Takahashi Toshiaki Takahashi |
author_facet |
Taichi Miyawaki Hirotsugu Kenmotsu Hiroaki Kodama Naoya Nishioka Eriko Miyawaki Nobuaki Mamesaya Haruki Kobayashi Shota Omori Ryo Ko Kazushige Wakuda Akira Ono Tateaki Naito Haruyasu Murakami Keita Mori Hideyuki Harada Masahiro Endo Kazuhisa Takahashi Toshiaki Takahashi |
author_sort |
Taichi Miyawaki |
title |
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study |
title_short |
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study |
title_full |
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study |
title_fullStr |
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study |
title_full_unstemmed |
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study |
title_sort |
association between oligo-residual disease and patterns of failure during egfr-tki treatment in egfr-mutated non-small cell lung cancer: a retrospective study |
publisher |
BMC |
publishDate |
2021 |
url |
https://doaj.org/article/6452d84482df43b7a070b79879e835ef |
work_keys_str_mv |
AT taichimiyawaki associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT hirotsugukenmotsu associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT hiroakikodama associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT naoyanishioka associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT erikomiyawaki associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT nobuakimamesaya associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT harukikobayashi associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT shotaomori associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT ryoko associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT kazushigewakuda associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT akiraono associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT tateakinaito associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT haruyasumurakami associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT keitamori associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT hideyukiharada associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT masahiroendo associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT kazuhisatakahashi associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy AT toshiakitakahashi associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy |
_version_ |
1718418947408134144 |